Skip to main content
micro-community-banner
 
  • Saved

made a Post

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) ..... see more

Source : https://ascopubs.org/doi/full/10.1200/JCO.20.01814

  • Saved

made a Post

Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional ..... see more

Source : https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1873320?journalCode=ilal20

  • Saved

made a Post

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review.

Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe ..... see more

Source : https://europepmc.org/article/med/33518613

  • Saved

made a Post

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance ..... see more

Source : https://www.mdpi.com/1422-0067/22/3/1341/htm

  • Saved

made a Post

Immunodeficiency Secondary to Malignancies and Biologics

S. Shahzad Mustafa There are many causes for secondary immunodeficiency (SID), which commonly presents with increased risk of infections. B-cell malignancies (multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma) and chemotherapeutics ..... see more

Source : https://link.springer.com/chapter/10.1007/978-3-030-57157-3_21

  • Saved

made a Post

Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional ..... see more

Source : https://doi.org/10.1080/10428194.2021.1873320

  • Saved

made a Post

Identification of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis

Background Multiple myeloma is a hematologic disorder of abnormal plasma cell proliferation. Although there are some agents with different mechanisms in the clinic, the treatment of multiple myeloma is still ..... see more

Source : https://www.researchsquare.com/article/rs-153300/v1

  • Saved

made a Post

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy, and is characterized by the clonal expansion of malignant plasma cells. Despite the recent improvement in patient outcome due to ..... see more

Source : https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-021-00302-x

  • Saved

made a Post

Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma

Osteolytic lesions (OL) characterize symptomatic multiple myeloma. The mechanisms of how malignant plasma cells (PC) cause OL in one region while others show no signs of bone destruction despite subtotal ..... see more

Source : https://www.researchsquare.com/article/rs-146899/v1